Deep-learning-based de novo discovery and design of therapeutics that reverse disease-associated transcriptional phenotypes.
Europe PMC REST API · 學術索引收錄 · 來源發佈：Tue Mar 17 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:13 GMT+0000 (Coordinated Universal Time)
已保存的原文節選
Identifying drugs that reverse disease-associated transcriptomic features has been widely explored for drug repurposing, but its potential for de novo drug discovery remains underexplored. Here, we present gene expression profile predictor on chemical structures (GPS), a deep-learning-based drug discovery platform, guided by transcriptomic features, that screens large compound libraries and optimi
以上為帶出處的原文節選，完整內容請閱讀原始鏈接。自動收錄與主題分類不等於事實核驗。